Tag: livanova

LivaNova launches international pivotal study evaluating use of autonomic regulation therapy...

LivaNova has announced the first successful implantation of the Vitaria system in a patient enrolled in the Autonomic regulation therapy to enhance myocardial function...
LivaNova cardiac rhythm management

LivaNova completes US$190M sale of cardiac rhythm unit

LivaNova has finalised the US$190 million sale of its cardiac rhythm unit to MicroPort Scientific. The final terms of the deal commit LivaNova to paying...

Treating sleep apnoea in pacemaker patients improves AF therapy

This video has been sponsored by LivaNova. Sleep apnoea is a major chronic disease that can have cardiovascular consequences. Around 40–50% of people with atrial...
LivaNova Microport

LivaNova pulls out of cardiac rhythm management

LivaNova has entered a binding letter of intent for the sale of its cardiac rhythm management business franchise to Shanghai-based company MicroPort for $190...

Have you considered this sleeping burden of atrial fibrillation (AF)?

This video has been sponsored by LivaNova. AF is a growing epidemic affecting 33.5 million people today.1 Up to 91% of AF patients have co-morbidities.2 Among...
LivaNova cardiac rhythm management

LivaNova and MicroPort’s Rega family receives regulatory clearance in China

LivaNova and MicroPort’s Shanghai-based joint venture—MicroPort Sorin Cardiac Rhythm Management—has obtained approval for Rega. The family of pacemakers is now approved by the China...

Sensor-based CRT optimisation benefits sicker patients

This video has been sponsored by LivaNova. The RESPOND-CRT clinical trial is a relevant and significant study in the field of cardiac resynchronisation therapy. It...

CRT optimisation: Why a sensor-based strategy may be the optimal solution

This video has been sponsored by LivaNova. Over the past two decades there have been several optimisation strategies, whether they are echo-guided or EKG-guided, aimed...

Cardiac resynchronisation therapy with SonR automated feature helps to reduce hospitalisation...

Results from the RESPOND-CRT trial have shown a 35% risk reduction in hospitalisation at two years for heart failure patients implanted with cardiac resynchronisation...